BiotechTube

Edoxaban + Standard of Care

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Venous Thromboembolism (VTE)

Conditions

Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)

Trial Timeline

Mar 27, 2017 → May 24, 2022

NCT ID
NCT02798471

About Edoxaban + Standard of Care

Edoxaban + Standard of Care is a phase 3 stage product being developed by Daiichi Sankyo for Venous Thromboembolism (VTE). The current trial status is completed. This product is registered under clinical trial identifier NCT02798471. Target conditions include Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT).

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02798471Phase 3Completed

Competing Products

20 competing products in Venous Thromboembolism (VTE)

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
23
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
52
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
77
EdoxabanDaiichi SankyoPre-clinical
23
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
52
15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
77
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
77
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
77
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150 + enoxaparinAstellas PharmaPhase 2/3
65
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
65
YM150Astellas PharmaPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
65
Dalteparin sodium + Dalteparin sodium/aspirinEisaiPre-clinical
23
dalteparin injectionEisaiPhase 3
77
ONO-7684 + ONO-7684 PlaceboOno PharmaceuticalPhase 1
33
Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + (LMW) Heparin + Vitamin K AntagonistJohnson & JohnsonPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85